Malin shareholders in line for windfall after €119 million cash boost

Dublin-based biotech investment fund said €45 million of the proceeds from the sale will be used to repay a European Investment Bank loan, with the remaining cash to be returned to shareholders later this year

11th January, 2021
Malin shareholders in line for windfall after €119 million cash boost
Shares in Malin climbed as much as 10 per cent in early trading on the Irish stock exchange this morning following news of the Kymab sale

Malin, the Dublin-based biotech investment fund, said it will return capital to shareholders in the second half of this year following the sale of its stake in a drug company for up to €119 million.

Kymab, a Cambridge-based company developing treatments for the immune system, is being acquired by drug giant Sanofi in a deal worth up to $1.45 billion. Malin owns about 10 per cent of Kymab and will receive $112 million (€92 million)...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader



Unlimited Access for 1 Month, €19.99 Monthly thereafter

Get basic

*New subscribers only

You can cancel any time.



€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.




90 Day Pass

You can cancel any time.

2 Yearly



Unlimited Access for 2 Years

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

Chanelle founder invests €100k in Redesdale Group

Amryt seeks to have rare condition drug approved for payment

Icon to restore staff pay as business recovers from virus

Comment: Cutting-edge pharma research can bring investment to Ireland